NCT02157831 2018-08-17Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsAbramson Cancer Center at Penn MedicinePhase EARLY_PHASE1 Completed10 enrolled